Back to News
Market Impact: 0.2
Mayne Pharma Agrees To Settle IMVEXXY Patent Litigation With Teva Pharmaceutical
Source: Nasdaq
Legal & LitigationPatents & Intellectual PropertyHealthcare & Biotech
Mayne Pharma Group agreed to settle U.S. patent litigation with Teva Pharmaceuticals USA concerning IMVEXXY, its estradiol vaginal inserts for moderate to severe dyspareunia due to menopause. The article provides no settlement terms or financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
TEVA0.00
More News
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated
- After years of U.S. export bans, China plans its own: 40 AI, chip and solar technologies could be restricted
- Meta employees say Lula’s accounts restricted in Brazil election: Report
- MapLight Therapeutics CMO Erin Foff sells $124,068 in stock
- Meta grants itself right to scrape content from business customers for model training
- Phoenix Suns owner Mat Ishbia predicts team will win opening round playoff series — and the NBA season hasn't even started